Search Results

Victoria (Tori) Eskay has worked as a Physician Assistant since 2019. Prior to Maryland Oncology Hematology, Tori completed a fellowship in Emergency Medicine in Ann Arbor, Michigan at St. Joseph Mercy Hospital and then transitioned to working in primary care. Tori earned her Masters of Health Sciences from The George Washington University Physician Assistant program…

Dr. Shreya Sinha is a board-certified medical oncologist and hematologist at Maryland Oncology Hematology. Dr. Sinha earned a Bachelor of Science at the University of Michigan, Ann Arbor before attending medical school at St. George’s University. She went on to complete a residency in internal medicine and a fellowship in hematology and oncology at SUNY…

Lin Chen has worked as a Nurse Practitioner in Medical Oncology since 2021. She earned her first bachelor’s degree in Psychology at the University of the South and a second bachelor’s degree in Nursing at Johns Hopkins University. She has over 9 years of nursing experience within the acute care setting before earning her Master…

A Phase 3, Two-stage, Randomized, Multi-center, Controlled, Open-label Study Comparing Iberdomide Maintenance to Lenalidomide Maintenance Therapy after Autologous Stem Cell Transplantation (ASCT) in Participants with Newly Diagnosed Multiple Myeloma (NDMM) (EXCALIBER-Maintenance) (IM048022) MOA: Cereblon E3 ubiquitin ligase modulating agent, IMiD (thalidomide and its analogues) Key Eligibility Criteria: Confirmed diagnosis of symptomatic multiple myeloma (MM) Eastern…

A Phase 1/2 Open-Label, Dose-Escalation and Clinical Response Study of Quaratusugene Ozeplasmid in Combination with Osimertinib in Patients with Advanced, EGFR-Mutant, Metastatic Non-Small Cell Lung Cancer who have Progressed after Treatment with Osimertinib (ONC-003) MOA: Quaratusugene ozeplasmid (REQORSA™, GPX-001) has been shown to modulate the immune system Key Eligibility Criteria: Histologically/cytologically documented NSCLC Stage III/IV…

A Randomized, Multicenter, Placebo-controlled, Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Trastuzumab-based Therapy (FLAMINGO-01) MOA: GLSI-100 is the individual administration of GP2, a nine amino acid peptide of the HER2/neu protein,…